4.6. disorders diseases related calcium stones. 4.6.1. hyperparathyroidism [633-636] primary hpt responsible estimated 5% calcium stone formation. renal stones occur approximately 20% patients primary hpt. elevated levels pth significantly increase calcium turnover, leading hypercalcemia, hypercalciuria, bone disease. serum calcium may mildly elevated serum pth may within upper normal limits, therefore, repeated measurements may needed; preferably patient fasting. stones hpt patients may contain calcium oxalate calcium phosphate. nephrocalcinosis ckd may also occur. hpt suspected, neck exploration performed confirm diagnosis. surgery contraindicated, primary hpt treated cinacalcet. 4.6.2. granulomatous diseases granulomatous diseases, sarcoidosis, may complicated hypercalcemia hypercalciuria secondary increased calcitriol production. latter independent pth control, leading increased calcium absorption gastrointestinal tract suppression pth. treatment focuses activity granulomatous diseases may require steroids, hydroxychloroquine, ketoconazole. treatment reserved specialist. 4.6.3. primary hyperoxaluria patients primary hyperoxaluria (ph) referred specialised center, successful management requires experienced interdisciplinary team. main therapeutic aim reduce endogenous oxalate production, increased patients ph. approximately one-third patients ph type i, pyridoxine therapy normalises significantly reduces urinary oxalate excretion. goal adequate urine dilution achieved adjusting fluid intake 3.5-4.0 l/day adults (children 1.5 l/m2 body surface area) following circadian drinking regimen. therapeutic options preventing calcium oxalate crystallisation include hyper-diuresis, alkaline citrates, magnesium, lumasiran, rnai agent, new treatment reducing synthesis oxalate ph type 1 . treatment regimens are: pyridoxine ph type i: 5-20 mg/kg/day according urinary oxalate excretion patient tolerance;alkaline citrate: 3.25-9.75 g/day adults, 0.1-0.15 mq/kg/day children;magnesium: 200-400 mg/day (no magnesium case renal insufficiency).lumasiran: subcutaneous injection dose timing adjusted according body weight duration treatment:- initial dose: bodyweight < 10 kg: 6 mg/kg; bodyweight 10-20 kg: 6 mg/kg; bodyweight > 20 kg: 3 mg/kg; per month three months subcutaneous injection.- maintenance starting one month initial doses: bodyweight < 10 kg: 3 mg/kg 1-mal monthly; bodyweight 10-20 kg: 6 mg/kg every three months, bodyweight > 20 kg: 3 mg/kg 4.6.3.1. summary evidence recommendation management primary hyperoxaluria summary evidencelepyridoxine reduce urinary oxalate excretion primary hyperoxaluria type 1.3lumasiran reduce urinary oxalate excretion primary hyperoxaluria type 1.1b recommendationstrength ratingprescribe pyridoxine primary hyperoxaluria type 1.strongprescribe lumasiran primary hyperoxaluria type 1 responsive pyridoxine.strong 4.6.4. enteric hyperoxaluria [575,580,640-642] enteric hyperoxaluria particularly problematic condition patients intestinal malabsorption fat. abnormality associated high risk stone formation seen intestinal resection malabsorptive bariatric surgery, well crohn’s disease pancreas insufficiency. addition hyperoxaluria, patients usually present hypocitraturia due loss alkali. urine ph usually low, urinary calcium urine volume. abnormalities contribute high levels supersaturation calcium oxalate, crystalluria, stone formation, less frequently nephrocalcinosis ckd. specific preventive measures are: restricted intake oxalate-rich foods ;restricted fat intake ;calcium supplementation mealtimes enable calcium oxalate complex formation intestine [580,640-642];sufficient fluid intake balance intestinal loss water caused diarrhoea;alkaline citrates raise urinary ph citrate. summary evidencelealkaline citrates beneficial replace citrate loss raise urine ph.3calcium supplements meals enable calcium oxalate complex formation intestine.2breduction dietary fat oxalate beneficial intestinal malabsorption.3 recommendationsstrength ratingprescribe alkaline citrates enteric hyperoxaluria.weakadvise patients take calcium supplements meals.strongadvise patients follow diet low fat oxalate content.weak 4.6.5. renal tubular acidosis renal tubular acidosis caused severe impairment proton (type i) bicarbonate handling (type ii) along nephron. kidney stone formation occurs patients distal rta type i. figure 4.5 outlines diagnosis rta type i. table 4.7 shows acquired inherited causes rta. figure 4.5: diagnosis renal tubular acidosis bga = blood gas analysis; rta = renal tubular acidosis.** alternative ammonium chloride loading test using 1-day nh4cl load 0.05 g/kg body weight might provide similar results may better tolerated patient . second alternative cases could furosemide/fludrocortisone acidification test renal tubular acidosis acquired inherited. reasons acquired rta chronic obstructive uropathy, recurrent pyelonephritis, acute tubular necrosis, renal transplantation, analgesic nephropathy, sarcoidosis, sjögren syndrome autoimmune diseases, medullary sponge kidney, liver cirrhosis, sickle cell anaemia, idiopathic hypercalciuria, primary parathyroidism; may also drug-induced (e.g., amphotericin b, foscarnet, lithium, zonisamide, carbonic anhydrase inhibitors). table 4.7: inherited causes renal tubular acidosis type - inheritancegene/gene product/functionphenotypeautosomal dominantslc4a1/ae1/cl-bicarbonateexchangerhypercalciuria, hypokalaemia,rickets/osteomalaciaautosomal recessive hearing lossatp6v1b1/b1 sub-unit vacuolar h-atpase/proton secretionhypercalciuria, hypokalaemia,rickets/osteomalaciaautosomal recessiveatp6v0a4/a4 sub-unit vacuolar h-atpase/proton secretionhypercalciuria, hypokalaemia,rickets/osteomalacia rarely biallelic causative variants foxi1 wdr72 genes also identified. main therapeutic aim rta treatment restoring normal acid-base equilibrium. despite alkaline ph urine rta, alkalinisation using alkaline citrates sodium bicarbonate important normalising metabolic changes (intracellular acidosis) responsible stone formation (table 4.8) bone demineralisation. alkali load reduces tubular re-absorption citrate, turn normalises citrate excretion. therapeutic success monitored venous blood gas analysis (base excess: ± 2.0 mmol/l) complete rta. excessive calcium excretion (> 8 mmol/day) persists re-establishing acid-base equilibrium, thiazides may lower urinary calcium excretion. table 4.8: pharmacological treatment renal tubular acidosis biochemical risk factorindication pharmacologicaltherapymedicationhypercalciuriacalcium excretion > 8 mmol/dayhydrochlorothiazide*,- adults: 25 mg/day initially, 50 mg/day- children: 0.5-1 mg/kg/dayalternatives adults:chlorthalidone 25 mg/dindapamide 2.5 mg/dinadequate urine phcitrate excretion male < 1.7 mmol/day, female < 1.9 mmol/dayalkaline citrate, 3.25-9.75 g/day divided three dosesorsodium bicarbonate, 1.5 g, three times daily * patients hydrochlorothiazide advised get skin checked regular basis higher risk developing nmsc forms melanoma. patients history skin cancer, indication treatment hydrochlorothiazide thoroughly reviewed [621-623] 4.6.5.1. summary evidence recommendations management tubular acidosis summary evidencelealkaline citrates beneficial distal renal tubular acidosis.2bthiazides beneficial hypercalciuria.1a recommendationsstrength ratingprescribe alkaline citrates distal renal tubular acidosis.strongaddress normalization bicarbonatremia citraturia alkaline citratestrongprescribe thiazides hypercalciuria.strong 4.6.6. nephrocalcinosis nephrocalcinosis (nc) refers increased calcium crystal deposition within renal cortex medulla occurs alone combination renal stones. various metabolic causes. main causes hpt, primary enteric hyperoxalurias, genetic acquired rta, medullary sponge kidney, vitamin metabolic disorders, sarcoidosis, idiopathic hypercalciuria hypocitraturia, genetic disorders, including dent’s disease bartter’s syndrome. many causes nc mean single standard therapy. therapeutic attention must focus underlying metabolic genetic disease, frequent association ckd minimising biochemical risk factors. 4.6.6.1. diagnosis diagnosis requires following blood analysis: pth (in case increased calcium levels), vitamin metabolites, vitamin a, sodium, potassium, magnesium, chloride, bicarbonate. urinalysis investigate urine ph profile different times day daily urine volume, specific weight urine, levels calcium, oxalate, phosphate, uric acid, magnesium, citrate .